National Tuberculosis and Leprosy Conrol Programme
Guidelines for treatment of drug-susceptible tuberculosisand patient care
2017 Update
Accessed November 2, 2017
Expert opinion of the European Tuberculosis Laboratory Initiative core group members for the WHO European Region.
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more
CBR Advisory Working Group | Co-ordinator: Karen Heinicke-Motsch
Evidence from Low and Middle Income Countries
Sixth Meeting of the mhGAP Forum Hosted by WHO in Geneva on 4-5 September 2014 Summary Report
This document has been developed to provide training and guidance on how to integrate a human rights approach in mental health and related areas, based on international human rights instruments, in particular the UN Convention on the Rights of Persons with Disabilities (CRPD).
Experiences from Indonesia, Kenya, Uganda and Ukraine
Bain LE, et al. BMJ Glob Health 2017;2:e000227. doi:10.1136/bmjgh-2016-000227